Please Wait.....
Report
Global Radiotheranostics Market By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others), By Application (Oncology v/s Non-Oncology), By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others) and By Region, Competition Forecast and Opportunities, 2027
Market Report I 2022-10-01 I 118 Pages I TechSci Research
Global radiotheranostics market is anticipated to register growth at an impressive CAGR in the forecast period, 2023-2027. Radiotheranostics is a process that involves the use of radionuclides for paired imaging and therapy agents. It is a systematic integration of targeted diagnostics and therapeutics. The growing prevalence of cancer and the rising adoption of injectable radiopharmaceuticals that have antitumor effects are majorly contributing to the global radiotheranostics market growth. The increasing usage of radiotheranostics in cancer diagnosis and management is providing a thrust to the market. Radiotheranostics have enhanced therapy efficacy, the ability to manage adverse and critical health situations, which results in improved patient outcomes.
Moreover, the recent research and developments in the radiotheranostics field is creating a positive impact on the market growth. For instance, there have been major outcomes in radiotheranostics for prostate cancer and neuroendocrine tumors. Additionally, the regulatory approval of numerous radiotheranostics pairs is expected to boost their adoption for cancer treatments. For instance, the approvals of new radiotheranostics agents such as 177Lu-PSMA-617 and 177Lu-DOTATATE have resulted in the resurgence of research in the field of radiotheranostics and have proliferated the number of clinical trials and testing several other novel radiotheranostics. Furthermore, the continuous support in research and development to keep pace with current momentum in radiotheranostics innovations is supporting the market growth. Additionally, the clinical use of radiotheranostics agents have increased dramatically due to the successful strides that have been made in the understanding of underlying biology of cancer and enhanced methods for synthesizing and designing targeted theragnostic agents. This, in turn, is positively influencing the market growth.
Structural imaging is the most crucial component of staging, diagnosing, and assessing responses in cancer patients. However, patients and healthcare professionals are increasingly seeking non-invasive methods of investigating tumor phenotypes and assessing molecular and functional responses to therapy. Therefore, radiotheranostics, a combination of non-invasive diagnostic imaging with targeted therapy, is widely being implemented. As a result, the global market for radiotheranostics is anticipated to propel at a rapid pace in the coming years.
Market Segmentation
The global radiotheranostics market is segmented by radioisotope, application, end user, competitive landscape, and regional distribution. Based on the radioisotope, the market is differentiated between technetium-99, gallium-68, iodine-131, iodine-123, 18f, y-90, lutetium (lu) 177, copper (cu) 67, copper (cu) 64, and others. By offering the market is fragmented between oncology and non-oncology. The oncology segment is further bifurcated into thyroid cancer, neuroendocrine cancer, hepatocellular carcinoma, multiple myeloma and lymphoma, and other. The non-oncology application segment is further divided between joint infections, arthritis, bone pain, and others. On the basis of end user, the global market is segmented between hospitals & clinics, pharmaceutical & biotechnology companies, and others. The market analysis also studies the regional segmentation to devise regional market segmentation, divided among North America, Europe, Asia Pacific, Middle east and Africa, South America.
Company Profile
TransCode Therapeutics, Inc., Curium SAS, GE Healthcare Inc., Bayer AG, Lantheus Medical, Imaging, Inc., Novartis AG, Spectrum Pharmaceuticals, Inc., Ipsen S.A., Actinium Pharmaceuticals, Inc. (ATNM), Nordic Nanovector ASA, Y-mAbs Therapeutics, Inc., Sofie Biosciences, Inc., Terumo Corporation, Sirtex Medical Limited, and Boston Scientific Corporation are the leading market players responsible for the growth of global radiotheranostics market.
Report Scope:
In this report, global radiotheranostics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
- Global Radiotheranostics Market, By Radioisotope:
o Technetium-99
o Gallium-68
o Iodine-131
o Iodine-123
o 18F
o Y-90
o Lutetium (Lu) 177
o Copper (Cu) 67
o Copper (Cu) 64
o Others
- Global Radiotheranostics Market, By Application:
o Oncology
- Thyroid Cancer
- Neuroendocrine Cancer
- Hepatocellular Carcinoma
- Multiple Myeloma
- Lymphoma, Others
o Non-Oncology
- Joint Infections
- Arthritis
- Bone Pain
- Others
- Global Radiotheranostics Market, By End User:
o Hospitals & Clinics
o Pharmaceutical & Biotechnology Companies
o Others
- Global Radiotheranostics Market, By Region:
o North America
- United States
- Mexico
- Canada
o Europe
- France
- Germany
- United Kingdom
- Italy
- Spain
o Asia Pacific
- China
- India
- South Korea
- Japan
- Australia
o Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
o South America
- Brazil
- Argentina
- Colombia
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in global radiotheranostics market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. Product Overview
2. Research Methodology
3. Executive Summary
4. Impact of COVID-19 on Global Radiotheranostics Market
5. Voice of Customer
5.1. Radiotheranostics Awareness
5.2. Cancer Prevalence, By Gender
5.3. Cancer Prevalence, By Age Group
5.4. Cancer Prevalence, Region
5.5. Benefits of Using Radiotheranostics
6. Clinical Trial Analysis
7. Patent Analysis
8. Global Radiotheranostics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
8.2.2. By Application (Oncology v/s Non-Oncology)
8.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
8.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain, Others)
8.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
8.2.4. By Region
8.2.5. By Company (2021)
8.3. Product Market Map
9. North America Radiotheranostics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
9.2.2. By Application (Oncology v/s Non-Oncology)
9.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
9.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain, Others)
9.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
9.2.4. By Country
9.3. North America: Country Analysis
9.3.1. United States Radiotheranostics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Radioisotope
9.3.1.2.2. By Application
9.3.1.2.3. By End User
9.3.2. Mexico Radiotheranostics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Radioisotope
9.3.2.2.2. By Application
9.3.2.2.3. By End User
9.3.3. Canada Radiotheranostics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Radioisotope
9.3.3.2.2. By Application
9.3.3.2.3. By End User
10. Europe Radiotheranostics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
10.2.2. By Application (Oncology v/s Non-Oncology)
10.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
10.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain, Others)
10.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
10.2.4. By Country
10.3. Europe: Country Analysis
10.3.1. France Radiotheranostics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Radioisotope
10.3.1.2.2. By Application
10.3.1.2.3. By End User
10.3.2. Germany Radiotheranostics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Radioisotope
10.3.2.2.2. By Application
10.3.2.2.3. By End User
10.3.3. United Kingdom Radiotheranostics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Radioisotope
10.3.3.2.2. By Application
10.3.3.2.3. By End User
10.3.4. Italy Radiotheranostics Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Radioisotope
10.3.4.2.2. By Application
10.3.4.2.3. By End User
10.3.5. Spain Radiotheranostics Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1. By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1. By Radioisotope
10.3.5.2.2. By Application
10.3.5.2.3. By End User
11. Asia-Pacific Radiotheranostics Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
11.2.2. By Application (Oncology v/s Non-Oncology)
11.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
11.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain, Others)
11.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
11.2.4. By Country
11.3. Asia-Pacific: Country Analysis
11.3.1. China Radiotheranostics Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Radioisotope
11.3.1.2.2. By Application
11.3.1.2.3. By End User
11.3.2. India Radiotheranostics Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Radioisotope
11.3.2.2.2. By Application
11.3.2.2.3. By End User
11.3.3. South Korea Radiotheranostics Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Radioisotope
11.3.3.2.2. By Application
11.3.3.2.3. By End User
11.3.4. Japan Radiotheranostics Market Outlook
11.3.4.1. Market Size & Forecast
11.3.4.1.1. By Value
11.3.4.2. Market Share & Forecast
11.3.4.2.1. By Radioisotope
11.3.4.2.2. By Application
11.3.4.2.3. By End User
11.3.5. Australia Radiotheranostics Market Outlook
11.3.5.1. Market Size & Forecast
11.3.5.1.1. By Value
11.3.5.2. Market Share & Forecast
11.3.5.2.1. By Radioisotope
11.3.5.2.2. By Application
11.3.5.2.3. By End User
12. South America Radiotheranostics Market Outlook
12.1. Market Size & Forecast
12.1.1. By Value
12.2. Market Share & Forecast
12.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
12.2.2. By Application (Oncology v/s Non-Oncology)
12.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
12.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain, Others)
12.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
12.2.4. By Country
12.3. South America: Country Analysis
12.3.1. Brazil Radiotheranostics Market Outlook
12.3.1.1. Market Size & Forecast
12.3.1.1.1. By Value
12.3.1.2. Market Share & Forecast
12.3.1.2.1. By Radioisotope
12.3.1.2.2. By Application
12.3.1.2.3. By End User
12.3.2. Argentina Radiotheranostics Market Outlook
12.3.2.1. Market Size & Forecast
12.3.2.1.1. By Value
12.3.2.2. Market Share & Forecast
12.3.2.2.1. By Radioisotope
12.3.2.2.2. By Application
12.3.2.2.3. By End User
12.3.3. Colombia Radiotheranostics Market Outlook
12.3.3.1. Market Size & Forecast
12.3.3.1.1. By Value
12.3.3.2. Market Share & Forecast
12.3.3.2.1. By Radioisotope
12.3.3.2.2. By Application
12.3.3.2.3. By End User
13. Middle East and Africa Radiotheranostics Market Outlook
13.1. Market Size & Forecast
13.1.1. By Value
13.2. Market Share & Forecast
13.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
13.2.2. By Application (Oncology v/s Non-Oncology)
13.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
13.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain, Others)
13.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
13.2.4. By Country
13.3. MEA: Country Analysis
13.3.1. South Africa Radiotheranostics Market Outlook
13.3.1.1. Market Size & Forecast
13.3.1.1.1. By Value
13.3.1.2. Market Share & Forecast
13.3.1.2.1. By Radioisotope
13.3.1.2.2. By Application
13.3.1.2.3. By End User
13.3.2. Saudi Arabia Radiotheranostics Market Outlook
13.3.2.1. Market Size & Forecast
13.3.2.1.1. By Value
13.3.2.2. Market Share & Forecast
13.3.2.2.1. By Radioisotope
13.3.2.2.2. By Application
13.3.2.2.3. By End User
13.3.3. UAE Radiotheranostics Market Outlook
13.3.3.1. Market Size & Forecast
13.3.3.1.1. By Value
13.3.3.2. Market Share & Forecast
13.3.3.2.1. By Radioisotope
13.3.3.2.2. By Application
13.3.3.2.3. By End User
14. Market Dynamics
14.1. Drivers
14.2. Challenges
15. Market Trends & Developments
16. SWOT Analysis: Global Radiotheranostics Market
17. Competitive Landscape (Inclusive of SWOT Analysis of Players Profiled)
17.1. TransCode Therapeutics, Inc.
17.2. Curium SAS
17.3. GE Healthcare Inc.
17.4. Bayer AG
17.5. Lantheus Medical Imaging, Inc.
17.6. Novartis AG
17.7. Spectrum Pharmaceuticals, Inc.
17.8. Ipsen S.A.
17.9. Actinium Pharmaceuticals, Inc. (ATNM)
17.10. Nordic Nanovector ASA
17.11. Y-mAbs Therapeutics, Inc.
17.12. Sofie Biosciences, Inc.
17.13. Terumo Corporation
17.14. Sirtex Medical Limited
17.15. Boston Scientific Corporation
18. Strategic Recommendations
(Note: The companies list can be customized based on the client requirements.)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security